SCHEMBL3214199

SCHEMBL3214199

CCOc1cc(N(Cc2cnco2)c2ccc(S(C)(=O)=O)cc2)ccc1OC(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.40
PDE4B Q07343 6/20 0.36
F7 P08709 2/20 0.35
F3 P13726 2/20 0.35
AAK1 Q2M2I8 3/20 0.33
CIT O14578 1/20 0.33
GAK O14976 1/20 0.33
PRKX P51817 1/20 0.33
PRKCQ Q04759 1/20 0.33
HASPIN Q8TF76 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
BMP2K Q9NSY1 1/20 0.33
PTGS2 P35354 4/20 0.33
PDE4A P27815 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3123335 0.85 RXRA (0.42) HRH4AAK1CITGAKPRKX
SCHEMBL3131933 0.84 HRH4 (0.41) HRH4PDE4BAAK1CITGAK
SCHEMBL3211858 0.83 HRH4 (0.40) HRH4PDE4BF7F3PTGS2
SCHEMBL3203252 0.82 HRH4 (0.40) HRH4PDE4BAAK1CITGAK
SCHEMBL3126123 0.81 HRH4 (0.38) HRH4PDE4BAAK1CITGAK
SCHEMBL3117544 0.81 HRH4 (0.39) HRH4AAK1CITGAKPRKX
SCHEMBL3127864 0.81 HRH4 (0.41) HRH4PDE4BAAK1CITGAK
SCHEMBL3216038 0.80 CYP4F2 (0.39) HRH4PDE4BAAK1CITGAK
SCHEMBL3203958 0.78 HRH4 (0.37) HRH4PDE4BAAK1CITGAK
SCHEMBL3129299 0.78 PDE4B (0.41) PDE4BPTGS2PDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B HRH4 442/4885PDE4B 2/4885F7 3964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.